A study published in 2012, shows that everolimus sensitivity varies between patients depending on their tumor genomes. A group of patients with advanced metastasic bladder carcinoma (NCT00805129) treated with everolimus revealed a single patient who had a complete response to everolimus treatment for 26 months. The researchers sequenced the genome of this patient and compared it to different reference genomes and to other patients' genomes. They found that mutations in TSC1 led to a lengthened duration of response to everolimus and to an increase in the time to cancer recurrence. The mutated TSC1 apparently had made these tumors vulnerable to treatment with everolimus.